Mianserin, an antidepressant kills Leishmania donovani by depleting ergosterol levels

Experimental Parasitology

Volumn 144, Issue 1, 2014, Pages 84-90

  Dinesh, Neeradi ^a   Kaur, Preet Kamal ^a   Swamy, Kayala Kambagiri ^a   Singh, Sushma ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Ergosterol; HMGR; HPLC; Leishmania; Mianserin

Indexed keywords

CHOLESTEROL; ERGOSTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MIANSERIN; MILTEFOSINE; TRYPTOPHAN;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; FLUORESCENCE SPECTROSCOPY; GROWTH INHIBITION; IC 50; IN VITRO STUDY; INHIBITION KINETICS; LEISHMANIA DONOVANI; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; VISCERAL LEISHMANIASIS;

ERGOSTEROL; HMGR; HPLC; LEISHMANIA; MIANSERIN;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPROTOZOAL AGENTS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOSTEROL; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; MACROPHAGES; MIANSERIN; SPECTROMETRY, FLUORESCENCE;

EID: 84904279488     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2014.06.004     Document Type: Article

References (32)

1. Aarsland D., Karlsen K. Neuropsychiatric aspects of Parkinson's disease. Curr. Psychiatry Rep. 1999, 1:61-68.
2. Arguelles N., Sanchez-Sandoval E., Mendieta A., Villa-Tanaca L., Garduno-Siciliano L., Jimenez F. Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 2010, 18:4238-4248.
3. Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004, 3:673-683.
4. De Souza W., Rodrigues J.C. Sterol biosynthesis pathway as target for anti trypanosomatid drugs. Interdiscip. Perspect. Infect. Dis. 2009, 642502.
5. Dinesh N., Pallerla D.S., Kaur P.K., Kishore Babu N., Singh S. Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme a reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies. Microb. Pathog. 2014, 66:14-23.
6. Jain S.K., Sahu R., Walker L.A., Tekwani B.L. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J. Vis. Exp. 2012, 1-14.
7. Kopera H. Anticholinergic and blood pressure effects of mianserin, amitriptyline and placebo. Br. J. Clin. Pharmacol. 1978, 5(1):29-34.
8. Li Y., Gao F., Shan F., Bian J., Zhao C. Study on the interaction between 3 flavonoid compounds and α-amylase by fluorescence spectroscopy and enzymatic kinetics. J. Food Sci. 2009, 74:C199-C203.
9. Marshall R.J. The pharmacology of mianserin - an update. Br. J. Clin. Pharmacol. 1983, 15(2):263-268.
10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
11. Mukherjee S., Mukherjee B., Mukhopadhyay R., Naskar K., Sundar S., Dujardin J.C. Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection. PLoS Negl. Trop. Dis. 2012, 6(12):e1987.
12. Murray H.W., Berman J.D., Davies C.R., Saravia N.G. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
13. Ng H.E., Raj S., Wong S., Tey D., Tan H.M. Estimation of fungal growth using the ergosterol assay: a rapid tool in assessing the microbiological status of grains and feeds. Lett. Appl. Microbiol. 2008, 46:113-118.
14. Olianas M.C., Dedoni S., Onali P. The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors. Br. J. Pharmacol. 2012, 167:1329-1341.
15. Pandey B.D., Pandey K., Kaneko O., Yanagi T., Hirayama K. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am. J. Trop. Med. Hyg. 2009, 80:580-582.
16. Peet M., Behagel H. Mianserin: a decade of scientific development. Br. J. Clin. Pharmacol. 1978, 5(1):5S-9S.
17. Pijl H., Ohashi S., Matsuda M., Miyazaki Y., Mahankali A., Kumar V. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000, 23:1154-1161.
18. Phan S.V., Kreys T.J.M. Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacother. J. Hum. Pharm. Drug Ther. 2011, 31:1017-1030.
19. Rai S., Dwivedi U.N., Goyal N. Leishmania donovani trypanothione reductase: role of urea and guanidine hydrochloride in modulation of functional and structural properties. Biochim. Biophys. Acta 2009, 1794:1474-1484.
20. Sagdinc S.G., Sahinturk A.E. Density functional theory and vibrational studies of mianserin and its hydrochloride and hydrobromide salts. J. Mol. Struct. 2012, 1021:53-62.
21. Saint-Pierre-Chazalet M., Ben Brahim M., Le Moyec L., Bories C., Rakotomanga M., Loiseau P.M. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes. J. Antimicrob. Chemother. 2009, 64:993-1001.
22. Schreiber S., Backer M.M., Kaufman J.P., Pick C.G. Interaction between the tetracyclic antidepressant mianserin HCl and opioid receptors. Euro. Neurol. 1998, 8:297-302.
23. Singh S., Dinesh N., Kaur P.K., Shamiulla B. Ketanserin, anantidepressant exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani. Parasitol. Res. 2014, 113:2161-2168.
24. Shimony O., Jaffe C.L. Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J. Microbiol. Methods 2008, 75:196-200.
25. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Inter. Health. 2001, 6:849-854.
26. Thornton S.J., Wasan K.M. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin. Drug Deliv. 2009, 6(3):271-284.
27. Urbina J.A. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997, 114:S91-S99.
28. Urbina J.A. New advances in the management of a long-neglected disease. Clin. Infect. Dis. 2009, 49:1685-1687.
29. Wakeling A. Efficacy and side effects of mianserin, a tetracyclic antidepressant. Postgrad. Med. J. 1983, 59:229-231.
30. Weldrick D.P., Chodacka B., Vogt R., Steenkamp D.J. The effect of buthionine sulfoximine on the growth of Leishmania donovani in culture. FEMS Microbiol. Lett. 1999, 173(1):139-146.
31. Zhang X., Yang M., Ma Y., Song J. Study on biological characteristics and inhibition kinetics of α-amylase inhibitor from white kidney beans. Food Sci. 2007, 28:29-31.
32. Zilberstein D., Dwyer D.M. Antidepressants cause lethal disruption of membrane function in the human protozoan parasite Leishmania. Science 1984, 226:977-979.